New European patent approval for Episurf Medical

ViewReleaseInStandardHtml

New European patent approval for Episurf Medical

The European patent office EPO has announced its intention to grant another European patent for Episurf Medical (NASDAQ: EPIS B). The patent, entitled “System of designing a guide tool and/or surgical kit tools and/or an implant comprising a positioning mark, covers specific features for accurate placement of Episurf Medical’s individualised joint implants.

"Episurf’s Episealer® technology contains a number of delicate features, and the implant positioning solution for correct placement of individualised implants is one of these. This patent contributes to a comprehensive IP protection of our implant technology”, comments Katarina Flodström, COO, Episurf Medical.

For more  information, please contact:

Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.

This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 14.30 CEST on 19 June 2019.